| Entry |
|
|---|
| Name |
Glatiramer acetate (JAN/USAN);
Copaxone (TN) |
|---|
| Product |
|
|---|
| Generic |
GLATIRAMER ACETATE (AJENAT PHARMACEUTICALS LLC), GLATIRAMER ACETATE (AJENAT PHARMACEUTICALS LLC), GLATIRAMER ACETATE (Italfarmaco SpA), GLATIRAMER ACETATE (Mylan Pharmaceuticals), GLATIRAMER ACETATE (Mylan Pharmaceuticals), GLATIRAMER ACETATE (Sun Pharmaceutical Industries), GLATIRAMER ACETATE (Sun Pharmaceutical Industries), GLATIRAMER ACETATE (UPSHER-SMITH LABORATORIES), GLATIRAMER ACETATE (Zydus Pharmaceuticals USA), GLATOPA (Bryant Ranch Prepack), GLATOPA (Bryant Ranch Prepack), GLATOPA (Sandoz) |
|---|
| Formula |
(C5H9NO4. C3H7NO2. C6H14N2O2. C9H11NO3)x. (C2H4O2)y
|
|---|
| Remark |
| Therapeutic category: | 3999 |
|
|---|
| Efficacy |
Immunomodulator, T cell receptor antagonist |
|---|
| Disease |
Multiple sclerosis [DS: H01490] |
|---|
| Target |
|
|---|
| Pathway |
| hsa04612 | Antigen processing and presentation |
|
|---|
| Interaction |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L03 IMMUNOSTIMULANTS
L03A IMMUNOSTIMULANTS
L03AX Other immunostimulants
L03AX13 Glatiramer acetate
D04318 Glatiramer acetate (JAN/USAN) <JP/US>
USP drug classification [BR:br08302]
Central Nervous System Agents
Multiple Sclerosis Agents
Glatiramer
D04318 Glatiramer acetate (JAN/USAN)
Therapeutic category of drugs in Japan [BR:br08301]
3 Agents affecting metabolism
39 Other agents affecting metabolism
399 Miscellaneous
3999 Others
D04318 Glatiramer acetate (JAN/USAN)
Target-based classification of drugs [BR:br08310]
Cell surface molecules and ligands
Cell adhesion molecules: Ig superfamiy
MHC
MHC1
D04318 Glatiramer acetate (JAN/USAN) <JP/US>
MHC2
D04318 Glatiramer acetate (JAN/USAN) <JP/US>
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D04318
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
